Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CNS disorders RNA interference-based therapeutics - Alnylam Pharmaceuticals

Drug Profile

Research programme: CNS disorders RNA interference-based therapeutics - Alnylam Pharmaceuticals

Latest Information Update: 28 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sirna Therapeutics
  • Developer Alnylam Pharmaceuticals; Sirna Therapeutics
  • Class Antidementias; Neuroprotectants; RNA; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical CNS disorders
  • No development reported Cerebral amyloid angiopathy; Neurodegenerative disorders
  • Discontinued Spinocerebellar degeneration

Most Recent Events

  • 28 Jan 2023 No recent reports of development identified for preclinical development in Cerebral-amyloid-angiopathy in USA (Parenteral)
  • 28 Jun 2022 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (Intrathecal, Injection)
  • 24 Dec 2021 Alnylam Pharmaceuticals submits CTA application to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for the treatment of Alzheimer’s disease and Cerebral amyloid angiopathy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top